Search Results - "Pozniak, AL"

Efficacy of Tenofovir Disoproxil Fumarate in Antiretroviral Therapy-Naive and -Experienced Patients Coinfected with HIV-1 and Hepatitis B Virus by Dore, Gregory J., Cooper, David A., Pozniak, Anton L., DeJesus, Edwin, Zhong, Lijie, Miller, Michael D., Lu, Biao, Cheng, Andrew K.

“…Background. Coinfection with human immunodeficiency virus type 1 (HIV-1) increases the risk of hepatitis B virus (HBV)-associated progressive liver disease…”
Get full text

Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers by WINSTON, Alan, BACK, David, FLETCHER, Carl, ROBINSON, Lesley, UNSWORTH, Jennifer, TOLOWINSKA, Izabela, SCHUTZ, Malte, POZNIAK, Anton L, GAZZARD, Brian, BOIFITO, Marta

“…Recent studies have described reduced absorption of certain protease inhibitors when administered with agents known to increase gastric pH. No clinically…”
Get full text

British HIV Association guidelines for the treatment of TB/HIV coinfection 2011 by Pozniak, AL, Coyne, KM, Miller, RF, Lipman, MCI, Freedman, AR, Ormerod, LP, Johnson, MA, Collins, S, Lucas, SB

Get full text

Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV by Gallant, Joel E, DeJesus, Edwin, Arribas, José R, Pozniak, Anton L, Gazzard, Brian, Campo, Rafael E, Lu, Biao, McColl, Damian, Chuck, Steven, Enejosa, Jeffrey, Toole, John J, Cheng, Andrew K

“…This randomized, open-label trial compared two regimens for the initial treatment of human immunodeficiency virus (HIV) infection: tenofovir disoproxil…”
Get full text

Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A 3-Year Randomized Trial by Gallant, Joel E, Staszewski, Schlomo, Pozniak, Anton L, DeJesus, Edwin, Suleiman, Jamal M. A. H, Miller, Michael D, Coakley, Dion F, Lu, Biao, Toole, John J, Cheng, Andrew K, for the 903 Study Group

“…CONTEXT Tenofovir disoproxil fumarate (DF) is a once-daily nucleotide analogue reverse transcriptase inhibitor. OBJECTIVE To evaluate the efficacy and safety…”
Get full text

Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir by WESTBY, Mike, LEWIS, Marilyn, WHITCOMB, Jeannette, YOULE, Mike, POZNIAK, Anton L, JAMES, Ian T, JENKINS, Tim M, PERROS, Manos, VAN DER RYST, Elna

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial by POZNIAK, Anton L, MORALES-RAMIREZ, Javier, BOVEN, Katia, KATABIRA, Elly, STEYN, Dewald, LUPO, Sergio H, SANTOSCOY, Mario, GRINSZTEJN, Beatriz, RUXRUNGTHAM, Kiat, RIMSKY, Laurence T, VANVEGGEL, Simon

“…TMC278 is a next-generation nonnucleoside reverse transcriptase inhibitor highly active against wild-type and nonnucleoside reverse transcriptase…”
Get full text

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 by van der Ryst, Elna, Fätkenheuer, Gerd, Pozniak, Anton L, Johnson, Margaret A, Plettenberg, Andreas, Staszewski, Schlomo, Hoepelman, Andy I M, Saag, Michael S, Goebel, Frank D, Rockstroh, Jürgen K, Dezube, Bruce J, Jenkins, Tim M, Medhurst, Christine, Sullivan, John F, Ridgway, Caroline, Abel, Samantha, James, Ian T, Youle, Mike

“…We assessed the efficacy and safety of 10-d monotherapy with the orally administered CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for…”
Get full text

Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients: 144-Week Analysis by Arribas, Jose R, Pozniak, Anton L, Gallant, Joel E, DeJesus, Edwin, Gazzard, Brian, Campo, Rafael E, Chen, Shan-Shan, McColl, Damian, Holmes, Charles B, Enejosa, Jeffrey, Toole, John J, Cheng, Andrew K

“…BACKGROUND:As antiretroviral regimens for the treatment of HIV infection improve, trials providing data on long-term follow-up are increasingly important…”
Get full text

Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients: Virologic, Immunologic, and Morphologic Changes-A 96-Week Analysis by Pozniak, Anton L, Gallant, Joel E, DeJesus, Edwin, Arribas, Jose R, Gazzard, Brian, Campo, Rafael E, Chen, Shan-Shan, McColl, Damian, Enejosa, Jeffrey, Toole, John J, Cheng, Andrew K

“…BACKGROUND:In antiretroviral-naive patients, tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV) demonstrated superior outcomes…”
Get full text

The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients by GALLANT, Joel E, WINSTON, Jonathan A, DEJESUS, Edwin, POZNIAK, Anton L, CHEN, Shan-Shan, CHENG, Andrew K, ENEJOSA, Jeffrey V

“…Cases of renal dysfunction in patients receiving tenofovir disoproxil fumarate (TDF) have been reported. We analyzed the renal safety of TDF compared with…”
Get full text

The influence of HIV status on single and multiple drug reactions to antituberculous therapy in Africa by Pozniak, A L, MacLeod, G A, Mahari, M, Legg, W, Weinberg, J

“…To document the influence of HIV status on drug reactions occurring in patients on antituberculous therapy in Harare, Zimbabwe. Retrospective cohort study…”
Get more information

Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents by COYNE, Katherine M, POZNIAK, Anton L, LAMORDE, Mohammed, BOFFITO, Marta

Get full text

Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial by Wilkin, Aimee, Pozniak, Anton L, Morales-Ramirez, Javier, Lupo, Sergio H, Santoscoy, Mario, Grinsztejn, Beatriz, Ruxrungtham, Kiat, Rimsky, Laurence T, Vanveggel, Simon, Boven, Katia

“…TMC278-C204 (NCT00110305), a 96-week trial of the nonnucleoside reverse transcription inhibitor (NNRTI) rilpivirine (RPV, TMC278) in 368 HIV-1-infected,…”
Get more information

Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects by Goebel, Frank, Yakovlev, Alexy, Pozniak, Anton L, Vinogradova, Elena, Boogaerts, Griet, Hoetelmans, Richard, de Béthune, Marie-Pierre P, Peeters, Monika, Woodfall, Brian

“…To evaluate antiviral activity, pharmacokinetics, tolerability and safety of TMC278, a non-nucleoside reverse transcriptase inhibitor (NNRTI), when given as a…”
Get full text

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy by DEAN, Gillian L, EDWARDS, Simon G, DE RUITER, Annemiek, POZNIAK, Anton L, IVES, Natalie J, MATTHEWS, Gail, FOX, Emma F, NAVARATNE, Lesley, FISHER, Martin, TAYLOR, Graham P, MILLER, Rob, TAYLOR, Chris B

“…To assess the risks and benefits of administering highly active antiretroviral therapy (HAART) during the treatment of tuberculosis (TB) in HIV-infected…”
Get full text

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: A randomized trial by SQUIRES, Kathleen, POZNIAK, Anton L, COAKLEY, Dion F, CHENG, Andrew, PIERONE, Gerald JR, STEINHART, Corklin R, BERGER, Daniel, BELLOS, Nicholaos C, BECKER, Stephen L, WULFSOHN, Michael, MILLER, Michael D, TOOLE, John J

“…Resistance to antiretroviral agents remains a leading cause of treatment failure for patients infected with HIV-1. To describe the efficacy and safety of…”
Get full text

The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool by REVELL, Andrew D, DECHAO WANG, BOYD, Mark A, EMERY, Sean, POZNIAK, Anton L, DE WOLF, Frank, HARRIGAN, Richard, MONTANER, Julio S. G, LANE, Clifford, LARDER, Brendan A

“…The optimum selection and sequencing of combination antiretroviral therapy to maintain viral suppression can be challenging. The HIV Resistance Response…”
Get full text

Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis by MICHAILIDIS, Christos, POZNIAK, Anton L, MANDALIA, Sundhiya, BASNAYAKE, Sheena, NELSON, Mark R, GAZZARD, Brian G

“…Some patients with HIV/tuberculosis (TB) coinfection who are on anti-TB treatment and highly active antiretroviral therapy (HAART) will develop an exacerbation…”
Get full text

An open-label assessment of TMC 125: a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance by GAZZARD, Brian G, POZNIAK, Anton L, VANT'KLOOSTER, Gerben A. E, ROSENBAUM, Willy, YENI, G. Patrick, STASZEWSKI, Schlomo, ARASTEH, Keikawus, DE DIER, Karin, PEETERS, Monika, WOODFALL, Brian, STEBBING, Justin

“…The development of resistance to any of the currently licensed non-nucleoside reverse transcriptase inhibitors (NNRTI) invariably leads to cross-resistance to…”
Get full text